quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·101d
PRRelease
Lipocine Inc. logo

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

LPCN· Lipocine Inc.
Health Care
Original source

Companies

  • LPCN
    Lipocine Inc.
    Health Care

Recent analyst ratings

  • Apr 6UpdateH.C. Wainwright-
  • Aug 26UpdateHC Wainwright & Co.$3.50
  • Jun 24UpdateCantor Fitzgerald$3.00

Related

  • SEC2d
    SEC Form DEFA14A filed by Lipocine Inc.
  • SEC2d
    SEC Form DEF 14A filed by Lipocine Inc.
  • SEC2d
    Lipocine Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER16d
    SEC Form 4 filed by Higuchi John W.
  • INSIDER17d
    SEC Form 4 filed by Higuchi John W.
  • INSIDER17d
    SEC Form 4 filed by Patel Mahesh V.
  • ANALYST17d
    Lipocine downgraded by H.C. Wainwright
  • INSIDER21d
    SEC Form 4 filed by Patel Mahesh V.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022